Podcasts about clinical trials

A mysterious dust fills a young family's apartment. The truth begins to unravel when the mother gets a call from the pediatrician - the monster deep within the walls has been unleashed. LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett. EP1 features Zak Orth, Jenny Maguire, Daphne Gaines, and Micheal Gaston. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes. Casting by Alaine Alldaffer and Lisa Donadio.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In part eight of this ten-part series, Dr. Paul Crane and Dr. Prashanth Ramachandran discuss the study findings and the potential impact on clinical practice.  Show reference:  https://jamanetwork.com/journals/jamaneurology/fullarticle/2824325

Interview with Roxana Mehran, MD, author of Preserving and Promoting Clinical Trial Representativeness: A Review of Existing Strategies and the Path Forward. Hosted by Robert Bonow, MD. Related Content: Preserving and Promoting Clinical Trial Representativeness

Send us a textCardiothoracic surgeon Dr. Mustafa "Dr. Kurk" Kurkluoglu joins cardiologist Dr. Michael Koren to discuss three mechanisms that affect heart health:Oxidative stress, dangerous charged particles that can damage cellsInflammation, an immune process that can get out of controlEndothelial dysfunction, cells that line blood vessels stop working properlyThe two doctors discuss what can be done to address some of these issues, including supplements and the evidence  (or lack thereof) supporting their use. Finally, they talk about Dr. Kurk's upcoming book, The Three Musketeers of Heart Health, which is available here.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Clinical researchers are set to launch immune-cell therapy clinical trials aimed at tackling treatment resistance in solid tumour, supported by a €11.9 million grant from the Disruptive Technologies Innovation Fund. The project is being spearheaded by a consortium from LIfT BiSciences, University of Galway, Galway University Hospitals and Hooke Bio. The funding award, announced by Minister for Enterprise, Trade and Employment, Peter Burke T.D., and Minister for Further and Higher Education, Research, Innovation and Science, James Lawless T.D., is the largest single grant awarded by the Disruptive Technologies Innovation Fund to date, with €5.9 million in direct funding going to University of Galway. The consortium will launch the first-in-human clinical trials of a ground-breaking neutrophil-based cancer immune-cell therapy developed by LIfT BioSciences, a client of Údarás na Gaeltachta with an Irish base in An Spidéal, Co. Galway. Neutrophils are part of the first line of defence in the body's immune response. The trial will focus on patients with metastatic cervical and head and neck cancer who have exhausted all standard treatments, including checkpoint inhibitors. Trials, which will be conducted at Galway University Hospitals, are expected to begin in 2026. The grant will support the clinical development of LIfT BioSciences' next-generation cell therapy designed to overcome resistance in solid tumours, known as Immuno-Modulatory Alpha Neutrophils (IMANs). University of Galway will contribute its deep expertise in oncology and cell therapy clinical trials, as well as in translating laboratory research into clinical applications, including predictive biomarkers. Hooke Bio will provide advanced analytical tools to optimise and assess how patients respond to this novel therapy. The study will first establish the safe and effective dose of immune-cell cancer therapy and then combine this treatment with other immune-based therapies to overcome resistance to these cancer treatments observed in some patients. Professor Sean Hynes, Consultant Histopathologist and Translational Cancer Researcher from University of Galway's School of Medicine and Lead Academic of the award said: "In partnership with LiFT BioSciences and Hooke Bio, we are very excited about University of Galway and Galway University Hospital being at the forefront of delivering on new oncological cellular therapies by using neutrophils, the body's own first responders, in the fight against cancer and ensuring patients in the West of Ireland have access to such cutting edge treatments." Professor Fidelma Dunne, Director of the Institute for Clinical Trials at University of Galway, said: "The Institute for Clinical Trials is proud to support this collaboration and look forward to working closely with Disruptive Technologies Innovation Fund partners LifT BioSciences and Hooke Bio, and with academic and clinical colleagues at the University and Galway University Hospital. The programme will bring a new therapy to patients with an unmet critical need. This will be a truly inspirational journey from basic science to a first in human trial as we deliver this novel cell therapy to cancer patients." Dr Michael McCarthy, Consultant Medical Oncologist and Principal Investigator at University Hospital Galway, added: "Cancer remains one of the most complex and dynamic diseases. IMANs have the potential to overcome key limitations of current cancer treatments by activating both the innate and adaptive branches of the immune system. This dual stimulation enables a comprehensive anti-tumour response, representing a transformative advancement in cancer therapy. We are pleased to receive this grant in collaboration with LIfT and Hooke Bio, and we look forward to accelerating the clinical development of this groundbreaking immunotherapy." Dr Andrew Finnerty Manager of the Centre for Cell Manufacturing Ireland at University of Galway, said: "We at the Centre for Cell Manufacturing Ire...

Lexi Silver is 15 years old. She lost both of her parents before she turned 11. That should tell you enough—but it doesn't. Because Lexi isn't here for your pity. She's not a sob story. She's not a trauma statistic. She's a writer, an advocate, and one of the most emotionally intelligent people you'll ever hear speak into a microphone.In this episode, Lexi breaks down what grief actually feels like when you're a kid and the adults around you just don't get it. She talks about losing her mom on Christmas morning, her dad nine months later, how the system let her down, and how Instagram trolls tell her she's faking it for attention. She also explains why she writes, what Experience Camps gave her, how she channels anger into poems, and what to say—and not say—to someone grieving.Her life isn't a Netflix drama. But it should be.And by the way, she's not “so strong.” She's just human. You'll never forget this conversation.RELATED LINKS• Lexi on Instagram: @meet.my.grief• Buy her book: The Girl Behind Grief's Shadow• Experience CampsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In episode 91 of the Summits Podcast, co-hosts Vince Todd, Jr. and Daniel Abdallah are joined by long-time Heroes Foundation volunteer Lori Wheeler. Tune in as Lori shares the cancer stories that have shaped her family and how she is raising her children to make a difference in their communities.

My guest is Dr. Nirao Shah, MD, PhD, a professor of psychiatry, behavioral sciences and neurobiology at Stanford University School of Medicine. We discuss how the brains of males and females differ and how those differences arise from different genes and hormones during fetal development, in childhood and adulthood. We discuss what drives male- versus female-specific behaviors and how hormonal fluctuations across the lifespan, including puberty, the menstrual cycle, menopause and aging – affect behavior, cognition and health. Additionally, we discuss how biology relates to gender identity and the impact of hormone therapies on brain circuits that regulate mating, parenting and social bonding. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman Maui Nui: https://mauinuivenison.com/huberman Eight Sleep: https://eightsleep.com/huberman LMNT: https://drinklmnt.com/huberman Function: https://functionhealth.com/huberman Timestamps 00:00:00 Nirao Shah 00:02:11 Mice, Humans & Brain, Biological Conservation 00:05:25 Hormones, Nature vs Nurture 00:07:13 Biological Sex Differences, Chromosomes & SRY Gene, Hormones 00:16:01 Sponsors: Maui Nui & Eight Sleep 00:19:09 Androgen Mutations, Feminization & Masculinization 00:22:04 SRY Gene; Animals & Sexual Trans-Differentiation 00:27:49 Hormones & Biological Brain Differentiation 00:31:22 Congenital Adrenal Hyperplasia, Androstenedione; Stress & Pregnancy 00:35:56 Genes, Brain Differentiation & Sexual Identity; Congenital Adrenal Hyperplasia 00:43:37 Testosterone, Estrogen & Brain Circuits 00:47:27 Sponsors: AG1 & LMNT 00:50:36 Intersex Individuals, Castration 00:52:23 Female Sexual Behavior, Brain, Testosterone & Pheromones 00:57:58 Identify as Heterosexual or Homosexual, Difference in Hormone Levels? 01:00:42 Gender, Sexual Orientation & Hormones; Hormone Replacement Therapy 01:10:21 Aromatization; Steroid Hormones & Gene Expression 01:15:00 Kids & Changing Gender Identity 01:19:05 Sexual Behavior, Refractory Period & Male Brain, Tacr1 Cells 01:21:31 Sponsor: Function 01:23:19 Hypothalamus, Dopamine, Prolactin, Cabergoline, Libido, Dopamine 01:27:05 Brain Circuits, Aggression & Sexual Behavior 01:32:40 Refractory Period; Age, Testosterone & Libido 01:36:07 Tacr1 Cells in Females, Periaqueductal Gray & Innate Behaviors 01:40:00 Parenting Behaviors & Brain Circuits; Pet Dogs 01:43:12 Oxytocin, Pair Bonding, Vasopressin; Biological Redundancy 01:47:22 Libido, Melanocortin, Tacr1 Neurons; GLP-1 Agonists, Clinical Trials; Kisspeptin 01:56:43 Female Brain Changes, Menstrual Cycle, Pregnancy, Menopause; Estrogen; Men & Hormone Fluctuation? 02:04:10 Life Experience Male vs Female, Sex Recognition, Behaviors & Context 02:16:05 Pain Management; Endocrine Disrupters, Gender Identity 02:21:03 Future Projects 02:24:29 Zero-Cost Support, YouTube, Spotify & Apple Follow & Reviews, Sponsors, YouTube Feedback, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

In part six of this ten-part series, Dr. Paul Crane and Dr. Prashanth Ramachandran discuss findings from a recent systematic review on pneumococcal meningitis, including the role of corticosteroid, the importance of treatment timing, and emerging adjunctive therapies that may improve patient outcomes. Show reference:  https://academic.oup.com/braincomms/article/6/3/fcae131/7644484

Send us a textCardiologist Dr. Michael Koren joins Kevin Geddings to talk about how we can learn a lot about medicine by knowing our history. The duo discuss how the history of healthcare, including smallpox inoculation in the 1800s, can inform us of the benefits of life-saving medicines like vaccines. They also talk about the history of obesity, the old city of St. Augustine, and how all of this relates to modern medicine.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Ever wondered how AI is being applied in the world of clinical trials where human lives are at stake?In this episode, Patrick Leung, CTO of Faro Health and former Google Duplex Engineering Lead, reveals how AI is transforming the clinical trial process — a process that can cost up to $2 billion per drug and take over 10 years to complete. Patrick reveals how Faro Health's AI systems generate complex clinical documentation in minutes instead of months in which hallucinations aren't acceptable, while navigating the strict regulatory requirements of the healthcare industry.Patrick also reflects on the evolution of AI technologies, the realities of large language models, and offers practical advice on how to thrive in the rapidly changing AI-driven era.Key topics discussed:The evolution of AI from image recognition and Google Duplex to LLMsHow Faro Health uses AI to transform clinical trial processThe challenges of applying AI in highly regulated industriesAI's potential to save time and millions in clinical trialsHow to tackle AI hallucinations and ensure high-quality outputsPatrick's thoughts on AGI and the future of AI beyond current capabilitiesThe viability and limitations of vibe codingStrategies and advice for individuals to thrive in the AI eraTimestamps:(00:00) Trailer & Intro(02:09) Career Turning Points(02:46) The Advancements of AI in the Past 10 Years(04:13) Non-LLM Types of AI(05:42) The Google Duplex(07:28) The Use of AI in Faro Health(09:44) Tackling AI Hallucination for Clinical Documents(12:25) Building the Evaluation Process on AI Results(14:28) AI as a Research Assistant(16:40) The Need of Building Custom AI Model(18:50) The Huge Impact of AI in Clinical Trials(21:15) The Regulations on Applying AI Technology(23:28) AI Success Stories in the Life Science Industry(25:16) The Possibility of AGI(28:36) The Path to AGI Using LLM(30:43) Actions People Should Take in the AI Era(35:48) AI Engineers and AI-Enabled Engineers(38:37) The Viability of Vibe Coding(41:03) Hiring AI Engineers(42:26) Important Engineer Attributes in the AI Era(44:23) Important Leader Attributes in the AI Era(46:59) The Room for Juniors in the AI Era(49:04) Inspirational Story of a Successful Junior(51:33) 3 Tech Lead Wisdom_____Patrick Leung's BioPatrick Leung is a Chief Technology Officer at Faro Health, a company at the forefront of optimizing clinical trial development through the use of artificial intelligence.In his role, he is instrumental in applying large language models and other AI technologies to enhance protocol design and outcomes for clinical trials. A native of New Zealand, Mr. Leung holds degrees in Computer Science and Finance.His career includes being a foundational member of an early e-commerce software company, where he played a key role in guiding the company from its initial stages to a successful initial public offering.Follow Patrick:LinkedIn – linkedin.com/in/puiwahTwitter – x.com/puiwahWebsite – farohealth.comLike this episode?Show notes & transcript: techleadjournal.dev/episodes/226.Follow @techleadjournal on LinkedIn, Twitter, and Instagram.Buy me a coffee or become a patron.

Send us a textGlobal Liver Institute President and CEO Larry Holden joins Roger Green to discuss recent Washington political and regulatory activities, their potential impact on the liver community, and ways we can respond.Larry starts by acknowledging that we are in for "dark times" under the current administration and describes some current government actions that are causing major setbacks, as well as others that have the potential to do so. Specifically, he details the challenges caused by budget cuts, reallocation of funds away from major universities, staff reductions and, along with them, a loss of expertise in technical areas where knowledge and experience are pivotal.Without minimizing these challenges, Larry proceeds to suggest actions that individuals and organizations can take to reduce losses to the greatest extent possible — and even create some "wins" — for people living with liver disease. He describes tactics for giving legislators something they value (mainly publicity and contacts) to build a relationship, gain access and create a sympathetic ear for liver community messages. The conversation itself shifts back and forth between some of the current challenges and the steps advocates can take to mitigate losses and, whenever possible, achieve "wins." Sometimes discouraging, sometimes educational, this is an essential conversation for all current and potential advocates for liver patients to hear.

Send us a textWelcome to The Oncology Journal Club Podcast Series 3Hosted by Professor Craig Underhill, Dr Kate Clarke & Professor Christopher Jackson | Proudly produced by The Oncology NetworkWelcome to Episode 6 of The Oncology Journal Club podcast. This is where we take a famously different approach to oncology research.Has non-operative management finally found its place in treating certain cancers? This episode unpacks compelling new data that might challenge the surgeon's traditional role for some patients with mismatch repair deficient tumours. While rectal cancer patients show remarkable complete response rates to immunotherapy, the story gets more complex across different cancer types – raising fascinating questions about tumour biology, patient selection and the future of organ preservation.We explore the delicate art of discussing immunotherapy outcomes with patients, navigating that narrow path between hope and realism. When treatments occasionally produce dramatic responses but more commonly offer limited benefits, how do oncologists communicate effectively without creating unrealistic expectations? Our hosts share practical strategies for these challenging conversations, emphasising that truly patient-centred care requires ongoing dialogue about prognosis.The oncology research world is evolving too, with updated CONSORT and SPIRIT guidelines transforming how clinical trials are designed and reported. These frameworks now mandate greater transparency, clearer safety reporting and increased patient involvement in study design – potentially leading to more trustworthy and applicable research outcomes.Plus, we examine an intriguing Chinese trial showing remarkable survival benefits from low-dose continuous capecitabine combined with aromatase inhibitors for metastatic breast cancer – a potential game-changer for resource-limited settings.From this year's AACR meeting, we highlight what might be the first change in standard of care for locally advanced head and neck cancer in two decades, along with promising targeted therapies for specific molecular subtypes of lung cancer. Join our expert hosts Professor Craig Underhill, Dr. Kate Clarke and Professor Christopher Jackson as they navigate these developments with their trademark blend of critical analysis, clinical wisdom and humour. Subscribe to The Oncology Newsletter to stay informed about the evolving landscape of oncology care and research.For links to the abstracts and bios of our hosts, head to the show notes on oncologynetwork.com.au.The Oncology Podcast - An Australian Oncology Perspective

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Effect of Frailty on Cardiovascular Clinical Trials: A Systematic Review and Meta-Analysis.

Michelle Andrews built a career inside the pharma machine long before anyone knew what “DTC” meant. She helped launch Rituxan and watched Allegra commercials teach America how to ask for pills by name. Then she landed in the cancer fun house herself, stage 4 breast cancer, and learned exactly how hollow all the “journey” slide decks feel when you're the one circling the drain.We talk about what happens when the insider becomes the customer, why pill organizers and wheat field brochures still piss her off, and how she fired doctors who couldn't handle her will to live. You'll hear about the dawn of pharma advertising, the pre-Google advocacy hustle, and what she wants every brand team to finally admit about patient experience.If you've ever wondered who decided windsurfing was the best way to sell allergy meds—or what happens when you stop caring if you make people uncomfortable—listen up.RELATED LINKSMichelle Andrews on LinkedInTrinity Life Sciences – Strategic AdvisoryJade Magazine – Ticking Time Bombs ArticleNIHCM Foundation – Breast Cancer StoryFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In the second episode of this two-part series, Dr. Justin Abbatemarco and Dr. Eric L. Voorn discuss how to integrate these coaching elements into practice to promote sustainable changes.  Show reference:  https://www.neurology.org/doi/10.1212/WNL.0000000000213781  https://www.sciencedirect.com/science/article/pii/S0960896625000458?via%3Dihub 

Dr. Rolland “Rollie” Carlson, CEO of Immunexpress is a veteran of the molecular diagnostics space. With over 25 years of leadership across Abbott, WaferGen, Asuragen, and more, Rollie is now focused on solving one of healthcare's most urgent crises: Sepsis.In this episode, we explore why sepsis, despite causing more than 48 million deaths annually remains so poorly understood and misdiagnosed. Rollie breaks down why early detection is so difficult, how gene expression profiling can finally distinguish between infectious and non-infectious inflammation and the real-world barriers to clinical trial design, FDA approval and physician adoption. We also cover military use cases, the lack of gold standards in sepsis diagnostics and what needs to change in how hospitals are incentivised to tackle this conditionTimestamps:[00:00:26] Why Sepsis Remains Underdiagnosed Globally[00:01:42] What Sepsis Actually Is and Why It's So Deadly[00:03:14] Who's Most at Risk: Age, Immunity, and Beyond[00:04:25] Detecting Sepsis Through Gene Expression[00:05:39] Why Blood Cultures Aren't Enough Anymore[00:09:14] FDA Approval Without a Gold Standard: The Regulatory Maze[00:12:39] Sepsis Isn't Always Bacterial and Why That Matters[00:15:20] How Physicians Are Reacting to New Molecular Tools[00:17:35] Beyond Sepsis: Expansion Into Infectious Diseases[00:18:57] From Marine Biologist to Diagnostics PioneerGet in touch with Rollie - https://www.linkedin.com/in/rollie-carlson-ph-d-059074a/ Learn more about Immunexpress - https://immunexpress.com/ Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwalSubscribe to the Podcast

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.George Tidmarsh, a biopharma veteran and adjunct professor at Stanford's medical school, has been appointed as the new head of the FDA's Center for Drug Evaluation and Research (CDER). His extensive industry experience will be valuable in his new government position. Data secrecy among cell and gene therapy developers is hindering progress in the field, causing fragmentation, stalling innovation, and delaying access to treatments. Meanwhile, Sarepta is facing challenges with its elevidys shipments and has lost platform designation for its technology. At the same time, Roche's phase III trial in COPD has failed, impacting the market path for astegolimab. Layoffs are happening at companies like GSK, Sail, and BioNTech. Experts are exploring new ways to overcome barriers in cell therapy production.Data secrecy among cell and gene therapy developers continues to hinder progress and access to treatments. Acadia has introduced a new team and pipeline with ambitious goals. Patients are fighting for access to Brainstorm's ALS drug after promising real-world data. Moderna's withdrawal of its flu vaccine has left combination flu/COVID-19 vaccines in limbo. In other news, Sarepta is facing challenges with its DMD gene therapy, Ultragenyx's gene therapy for Sanfilippo syndrome is rejected by the FDA, GSK's Blenrep loses an adcomm vote, and BMS' anemia drug Reblozyl fails a Phase III trial. The FDA is experiencing layoffs and employee turnover amid an overhaul. Vinay Prasad overruled reviewers on Moderna's COVID-19 shot for kids. Upcoming events include a webinar on AI for real-world research and job opportunities in the biopharma industry. Readers are encouraged to provide feedback and suggest topics for future coverage.

2025-07-18 Hosts Craig Lipset, Jane Myles, and Dr. Amir Kalali were joined by Shelly Barnes (UCB), Brittany Niland (Eli Lilly and Company) and Erica Coles Jacobsen (Konovo) for a discussion around healthcare providers (HCPs) and their involvement in clinical research. DTRA has partnered with Eli Lilly and Company and Konovo to better understand the sentiment of these HCPs around participating in clinical research. Using HCPs in trials can provide greater access for all patients, as well as continuing to build trust in research with providers. You can join TGIF-DTRA Sessions live on Friday's at 12:00 PM ET by checking out our LinkedIn. Follow the Decentralized Trials & Research Alliance (DTRA) on LinkedIn and X. Learn more about Membership options and our work at www.dtra.org.

The therapy delivers copies of the RORA gene to address multiple disease pathways.

Send us a textDr. Michael Koren joins Kevin Geddings to discuss how clinical research sites like ENCORE Research Group and medical information companies like MedEvidence can build and give back to communities by sharing what they know. Dr. Koren explains that medical experts can help people understand complex topics such as obesity and the skin condition hidradenitis suppurativa (HS) and help wash away some of the misinformation surrounding medicine.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Inside INdiana Business Radio for the afternoon of July 21, 2025. A Fort Wayne-based orthopedic startup is preparing to kick off a clinical study for a unique innovation. The next stage of the Ohio River Crossing project in southwest Indiana is getting underway. Plus, Indiana University Health is rethinking patient room design with its new downtown Indianapolis hospital. Get the latest business news from throughout the state at InsideINdianaBusiness.com.

Send us a textLate Permissive Hypercapnia for Mechanically Ventilated Preterm Infants: A Randomized Trial.Travers CP, Gentle SJ, Shukla VV, Aban I, Yee AJ, Armstead KM, Benz RL, Laney D, Ambalavanan N, Carlo WA.Pediatr Pulmonol. 2025 Jun;60(6):e71165. doi: 10.1002/ppul.71165.PMID: 40525736 Free PMC article. Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textEarly full enteral nutrition with fortified milk in very preterm infants: a randomized clinical trial.Salas AA, Gunawan E, Jeffcoat S, Nguyen K.Am J Clin Nutr. 2025 May;121(5):1117-1123. doi: 10.1016/j.ajcnut.2025.02.019. Epub 2025 Feb 21.PMID: 39986385 Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textIn this week's Journal Club, Ben and Daphna dive into several impactful neonatal studies shaping today's clinical decisions. The discussion opens with the MOCA Trial, exploring whether extending caffeine therapy in moderately preterm infants reduces hospital stays and improves outcomes. Despite reducing apnea episodes, the study highlights that extending caffeine treatment does not reduce time to discharge.Next, the team reviews a randomized trial on late permissive hypercapnia in mechanically ventilated preterm infants, showing that targeting slightly higher CO₂ levels can shorten invasive ventilation time without worsening long-term outcomes.Midway through the episode, we feature an EBNEO commentary with Dr. Kira McNellis on early full enteral nutrition with fortified milk in very preterm infants. She explains why fat-free mass is an important nutritional marker linked to neurodevelopment and why “negative” nutrition studies still matter for clinical practice.Other key papers include cumulative neonatal morbidities predicting long-term neurodevelopment, the long-term academic Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textExtended Caffeine for Apnea in Moderately Preterm Infants: The MoCHA Randomized Clinical Trial.Carlo WA, Eichenwald EC, Carper BA, Bell EF, Keszler M, Patel RM, Sánchez PJ, Goldberg RN, D'Angio CT, Van Meurs KP, Hibbs AM, Ambalavanan N, Cosby SS, Newman NS, Vohr BR, Walsh MC, Das A, Ohls RK, Fuller J, Rysavy MA, Ghavam S, Brion LP, Puopolo KM, Moore R, Baack ML, Colaizy TT, Baserga M, Osman AF, Merhar SL, Poindexter BB, DeMauro SB, Kumar V, Cotten CM; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network.JAMA. 2025 Jun 24;333(24):2154-2163. doi: 10.1001/jama.2025.5791.PMID: 40294395 Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

On the Friday, July 18 edition of Georgia Today: Protests against President Donald Trump take place across Georgia; a clinical trial aims to address the state's high rates of HIV; and knowing the difference between flood terms could help keep you safe in an emergency. 

In this episode of Onc Now, host Jonathan Sackier is joined by Jean Abraham, Professor of Precision Breast Cancer Medicine at the University of Cambridge, to delve into the future of integrated cancer medicine, the evolving role of clinical trials, and how precision oncology is redefining outcomes for patients with breast cancer across the UK.  Timestamps  00:00 – Introduction  01:28 – Quickfire round  09:50 – Cambridge institutes for precision medicine  12:53 – Predictive/prognostic tools in breast cancer  15:33 – The future of breast cancer clinical trials  18:34 – Integrating genomic data  22:31 – Addressing cost barriers  24:22 – How AI is transforming breast cancer care  28:08 – Why oncology?  30:04 – A message to non-oncologists  31:54 – Abraham's three wishes for healthcare  

In part one of this two-part series, Dr. Justin Abbatemarco and Dr. Eric L. Voorn discuss how exercise remains essential for people with neuromuscular disorders, even amid limited pharmaceutical options and safety concerns.  Show reference:  https://www.neurology.org/doi/10.1212/WNL.0000000000213781 https://www.sciencedirect.com/science/article/pii/S0960896625000458?via%3Dihub

This panel was recorded June 26, 2025.⁠⁠⁠⁠ We hope you'll join us live in the future to ask your own questions and participate in the attendee chat! See similar events on demand and read other free MedTech resources at RQMplus.com.SummaryHear leading neurology innovators discuss how to navigate complex regulatory pathways, accelerate approvals, and reduce risk in bringing groundbreaking neurological devices to market.LinkedIn panelist and moderator profiles 

Did you know that people who have received a kidney transplant are at a much higher risk for skin cancer? We sat down with experts to discuss how you can lower your risk. In this episode we heard from: Dr. Cerrene Giordano is a dermatologist and Mohs Micrographic surgeon at Roswell Park Comprehensive Cancer Center in Buffalo, New York. She specializes in treating skin cancers, particularly in patients who are high risk such as those who have received organ transplants, have weakened immune systems, or a genetic predisposition to skin cancer development. Her expertise includes skin cancer surgery, wound reconstruction, and the management of skin cancers such as melanoma, basal cell carcinoma, and squamous cell carcinoma, to name a few. Dr. Giordano is also involved in research aimed at improving pain management following dermatologic surgeries and exploring advanced imaging techniques to enhance surgical outcomes. Kent Bressler is a retired RN who was diagnosed with FSGS in 1984, and received a living donor transplant from his brother Kip in 1987. Kent is an active advocate for preemptive kidney transplant and has on the recommendation of NKF worked closely with the DoD and PCORI as a consumer peer reviewer. He is an NKF peer mentor and advocate who has collaborated on an editorial “Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of Chronic Kidney Disease,” published in AJKD in 2019. He will also be participating in the development of the new NKF Patient Network serving on the Data Input and Integration Committee. He has been an active hill advocate for the NKF for six years and was the proud recipient of the 2017 Richard K. Salick Advocacy Award. Kent is also an Army Veteran and retired from the Veterans administration as an RN. He is the co-founder of Kidney Solutions a not for profit program in Texas that assists patients and families in the transplant process and in finding a donor. He is currently an assistant team leader for Region 7. Kent and Cathy Bressler have been married for 56 years and their family consists of Gretchen and Todd Rossington and their son Colt and Celeste and Alex Brown and their children John Banks, Catherine and Alexis Brown. Risa Simon is a passionate author, speaker, mentor, kidney patient coach and advocate. As the founder and CEO of The Proactive Path and the TransplantFirst Academy, her mission is to help all kidney disease patients advocate for their best life possible—the life she now lives. As a preemptive kidney transplant recipient, Risa was able to circumvent the need for dialysis. This is her hope for all eligible kidney patients. Risa gives back a good portion of her time by serving on various advisory committees, such as the National Kidney Foundation's (NKF's) Kidney Action committee, the American Association of Kidney Patients (AAKP) program and convention committees and she chairs the Phoenix Chapter's Polycystic Kidney Disease (PKD) education committee.  She is also a member of the PKD Legacy Society and serves as a Peer Mentor for the National Kidney Foundation (NKF). Risa's message is all about empowering kidney patients to bring their voice to life.    Additional Resources: Dr. Cerrene Giordano Protect the Skin You're In Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.  

Dr. Roy Ligresti, chief of gastro-enterology at Hackensack University Medical Center in New Jersey tells Megan Lynchthat coffee is filled 'with a rich anti-oxident load,' but warns against a new trend of using the liquid in an enema.

Send us a textPolycystic kidney disease (PKD) is the most common inherited kidney disease. Those with PKD have a 50% chance to pass it on to their children and have progressively worse kidney function as they age. World-known PKD researcher Dr. Fouad Chebib joins Dr. Michael Koren to discuss the symptoms, risks, genetic cause, and treatment options for PKD. They also get into some new treatement methods being explored in clinical trials and what the future of PKD treatment may look like.Dr. Chebib leads the Polycystic Kidney Disease Foundation Center of Excellence and the Discovery and Translational PKD Research Laboratory at the Mayo Clinic, Florida.The Mayo Clinical Polycystic Kidney Disease (PKD) Resource Center includes many article by Dr. Chebib himself.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Welcome back to Ditch the Lab Coat, the podcast where we break down the fascinating world of medicine with a blend of scientific skepticism and real-world insight. In today's episode, we dive deep into the mysteries of the vagus nerve—a nerve so ancient and essential, it's been called the “conductor” in the symphony of human physiology.Join host Dr. Mark Bonta as he sits down with Dr. Kevin Tracey, neurosurgeon, president and CEO of the Feinstein Institutes for Medical Research, and a pioneer in the world of bioelectronic medicine. Dr. Tracey's breakthrough research has shown us that the vagus nerve is far more than just a conduit for signals—it's a key player in managing inflammation, regulating our immune system, and maybe even shaping the future of medicine.In this conversation, you'll explore the mind-bending complexity of the nervous system, discover how cutting-edge science is redefining how we treat diseases like rheumatoid arthritis and long Covid, and learn how a tiny chip implanted in the neck might one day replace whole classes of immune-suppressing drugs. Dr. Tracey shares metaphors, straight talk about medical myths, and a vision for a future where reprogramming the body's reflexes could offer relief to millions.Get ready for a journey that's equal parts awe-inspiring and practical, as we unpack the true potential (and real-world considerations) of harnessing the vagus nerve's power. Whether you're a healthcare professional, a science nerd, or just someone searching for new answers, this episode invites you to see medicine in a whole new way. Resources : ( https://feinstein.northwell.edu/ )Episode HighlightsVagus Nerve Complexity Unveiled — We're only scratching the surface of understanding the vagus nerve's vast, intricate network and its essential bodily roles.Inflammation: Friend and Foe — Inflammation is vital short-term, but when uncontrolled, it's destructive and underlies many autoimmune and chronic diseases.Nervous-Immune System Interplay — The nervous and immune systems communicate reflexively, with nerves directly capable of controlling immune and inflammatory responses.Bioelectronic Treatments Emerge — Vagus nerve stimulation—via implanted chips—shows promise for conditions like rheumatoid arthritis without full-body immunosuppression risks.Individualized Nerve Fiber Functions — Each of the 200,000 vagus fibers controls specific functions, forming a body-wide symphony of precision responses.Not All Self-Help Fits — Lifestyle hacks can support vagus health, but serious disease often requires targeted nerve stimulation, not general wellness.Caution Against Online Misinformation — Vagus nerve advice online is often oversimplified or inaccurate; nuance and scientific backing are essential.Lifestyle Still Matters — Balanced diet, sleep, exercise, and community all help regulate vagus nerve tone and reduce chronic stress.Future Disease Applications Possible — Vagus stimulation may treat IBD, MS, and neurodegenerative or psychiatric conditions as research evolves.Episode Timestamps6:25 — Exploring Nervous System Complexity9:08 — Vagus Nerve Controls Inflammation11:05 — Vagus Nerve: Brain Signals Control Inflammation15:45 — Nervous System's Role in Immunity20:43 — Understanding Your Vagus Nerves23:25 — Vagus Nerve Health and Research25:12 — Vagus Nerve Stimulation Insights29:36 — Vagus Nerve Stimulator: Inflammation Therapy32:13 — Neurotransmitter Effects on Cytokine Production38:22 — Minimizing Nerve Damage in Surgery39:30 — Vagus Nerve Stimulation Benefits43:42 — Exploring Vagus Nerve Mysteries46:42 — Vagus Nerve Stimulation for Autoimmune Diseases50:52 — Cold Plunges & Bioelectrical Future DISCLAMER >>>>>>    The Ditch Lab Coat podcast serves solely for general informational purposes and does not serve as a substitute for professional medical services such as medicine or nursing. It does not establish a doctor/patient relationship, and the use of information from the podcast or linked materials is at the user's own risk. The content does not aim to replace professional medical advice, diagnosis, or treatment, and users should promptly seek guidance from healthcare professionals for any medical conditions.   >>>>>> The expressed opinions belong solely to the hosts and guests, and they do not necessarily reflect the views or opinions of the Hospitals, Clinics, Universities, or any other organization associated with the host or guests.    Disclosures: Ditch The Lab Coat podcast is produced by (Podkind.co) and is independent of Dr. Bonta's teaching and research roles at McMaster University, Temerty Faculty of Medicine and Queens University. 

Dr. Anne Marie Morse walks into the studio like a one-woman Jersey Broadway show and leaves behind the best damn TED Talk you've never heard. She's a neurologist, sleep medicine doc, narcolepsy expert, founder of D.A.M.M. Good Sleep, and full-time myth buster in a white coat. We talk about why sleep isn't a luxury, why your mattress does matter, and how melatonin is the new Flintstones vitamin with a marketing budget. We unpack the BS around sleep hygiene, blow up the medical gaslighting around “disorders,” and dig into how a former aspiring butterfly became one of the loudest voices for patient-centered science. Also: naps, kids, burnout, CPAPs, co-sleeping, airport pods, the DeLorean, and Carl Sagan. If you think you're getting by on five hours of sleep and vibes, you're not. This episode will make you want to take a nap—and then call your doctor.RELATED LINKSdammgoodsleep.com: https://www.dammgoodsleep.comLinkedIn: https://www.linkedin.com/in/anne-marie-morse-753b2821/Instagram: https://www.instagram.com/dammgoodsleepDocWire News Author Page: https://www.docwirenews.com/author/anne-marie-morseSleep Review Interview: https://sleepreviewmag.com/practice-management/marketing/word-of-mouth/sleep-advocacy-anne-marie-morse/Geisinger Bio: https://providers.geisinger.org/provider/anne-marie-morse/756868SWHR Profile: https://swhr.org/team/anne-marie-morse-do-faasm/FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Tijana Milinic and Lia Barros, DNP, from the University of Washington take a deep dive into the world of pulmonary arterial hypertension (PAH) clinical trials and discuss why diversity and inclusion matter. They explore the hidden biases in medical research and the real-world consequences of exclusion. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @uwepidemiology  #phawareMD

Clinical trial transparency is a delicate balance of getting the right data to the right resources at the right time. Senior Partner Lisa Chamberlain James sits down with the President of Holtzople Consulting, Julie Holtzople, to discuss how to do just that. They discuss standardizing information for researchers, building trust, advice for best practices, and whether all this transparency is legally mandated – or simply the right thing to do.  

Dr. Justin Abbatemarco talks with Dr. Eric L. Voorn about the efficacy of combined personalized home-based aerobic exercise and coaching on physical fitness in people with neuromuscular diseases, compared with usual care.  Read the related article in Neurology®. Read the additional article that was referenced.  Disclosures can be found at Neurology.org. 

Back in Episode #401, we reported promising results from a Phase 2 clinical trial for vidofludimus calcium and its impact on progressive MS. This therapy is being developed by Immunic Therapeutics, and this week, Jason Tardio, Immunic's President and Chief Operating Officer, joins me to share some of the specifics of that clinical trial.    Jason will also shed light on why Immunic believes that vidofludimus calcium goes beyond merely slowing disability, potentially offering vital neuroprotection for MS patients, making it a potential game-changer. We're also sharing the encouraging results from a study that focused on the efficacy of neural stem cell transplantation as a remyelination therapy. We'll tell you about a study in the U.K. that measured disability progression among people with MS five years after undergoing autologous hematopoietic stem cell transplantation (aHSCT). You'll learn about an AI tool that can predict whether someone living with MS is likely to experience progression independent of relapse activity (PIRA) with a high degree of accuracy. We'll tell you where you can catch the International Progressive MS Alliance webcast featuring a panel of experts discussing the future role of digital tools in MS research. We'll explain how one of the less publicized aspects of the One Big Beautiful Bill Act will impact future MS care. And Crush MS is less than two weeks away! We're sharing all the details! We have a lot to talk about! Are you ready for RealTalk MS??! This Week: Encouraging results from a clinical trial for progressive MS.  :22 How a less-publicized aspect of the One Big Beautiful Bill Act will impact future MS patient care 1:18 A study looked at the efficacy of neural stem cell transplantation as a remyelination therapy  4:31 A study in the U.K. analyzed disability progression among people with MS five years after receiving autologous hematopoietic stem cell therapy (aHSCT)   7:42 Can AI accurately predict who will experience progression independent of relapse activity (PIRA)?  10:45 Don't miss the International Progressive MS Alliance webcast featuring experts discussing the future role of digital tools in MS research  12:40 Are you ready to support MS research while spending the afternoon in a Napa Valley vineyard? Get all the details to attend Crush MS  13:45 Jason Tardio, President and Chief Operating Officer of Immunic Therapeutics, discusses the recent Phase 2 clinical trial for vidofludimus calcium as a therapy for progressive MS  15:03 Share this episode  30:03 Have you downloaded the free RealTalk MS app?  30:23 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/411 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Become an MS Activist https://nationalmssociety.org/advocacy STUDY: Remyelination of Chronic Demyelinated Lesions With Directly Induced Neural Stem Cells https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awaf208/8185601 STUDY: Autologous Haemotopoietic Stem Cell Transplantation in the U.K.: A 20-Year Retrospective Analysis of Activity Haematological Outcomes from the British Society of Blood And Marrow Transplantation and Cellular Therapy https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.20199 STUDY: Deep Learning to Predict Progression Independent of Relapse Activity at a First Demyelinating Event https://academic.oup.com/braincomms/article/7/4/fcaf243/8185588 WEBCAST: A Discussion From the International Progressive MS Alliance's Digital Tools Workshop https://msif.org/news/2025/07/08/webcast-digital-tools EVENT: Crush MS https://crushms.org Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 411 Guest: Jason Tardio Privacy Policy

Axel Bex joins the show to discuss trials that he thinks have impacted RCC. We also discuss consolidative approaches, neoadjuvant trials and what can impact an academic career.

Thought leader Julio G. Martinez-Clark shares how his company in helping to bring medical innovation to the market sooner by conducting clinic trials in Latin America. About Julio: Julio G. Martinez-Clark stands at the forefront of clinical research transformation as the Ambassador of IAOCR/GCSA in the Americas and CEO of bioaccess®, where he bridges global quality standards with the world's growing MedTech, BioPharma, and Radiopharmaceutical ecosystems. With over two decades of cross-industry leadership spanning healthcare, telecommunications, and venture capital, Martinez-Clark has become the trusted partner for 100+ companies seeking accelerated regulatory approvals and cost-effective clinical trials worldwide. His unique fusion of technical expertise from Johns Hopkins Hospital infrastructure projects, regulatory acumen honed through UNESCO-aligned accreditations, and operational mastery of diverse global clinical trial landscapes positions him as the definitive authority on risk-mitigated medical innovation in emerging markets. Resources: Products discussed in the podcast: ReGelTec: https://regeltec.com/regeltec-chooses-colombia-bioacce-for-first-in-human-clinical-trial-of-hydrafil-system/   Spine Stabilization Technologies (SST): https://thespinemarketgroup.com/spinal-stabilization-technologies-ltd-announces-start-of-lopain-2-clinical-trial-in-south-america-for-lumbar-degenerative-disc-disease/   bioaccessla.com   Show sponsor:  The Cox 8 Table by Haven Medical

Dr. Arif Ali is a board-certified radiation oncologist at Peeples Cancer Institute at Hamilton Medical Center in Dalton, Georgia.For more information about Peeples Cancer Institute, call 844-PCI-HOPE or visit VitruvianHealth.com/cancer.This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.

Send us a textOver the past 100 years, the poorest Americans have shifted from being underweight to becoming the group most likely to be overweight. Dr. Michael Koren joins Kevin Geddings to explore some of the social determinants of health underlying this trend. They touch on the complex biological, economic, and environmental factors contributing to higher obesity rates among economically disadvantaged Americans.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

What if one prayer could change everything? In this episode of Behind the Human, Marc sits down with Matt Potter—co-founder of Pray.com—to unpack an extraordinary life story that began with a near-abortion and grew into one of the most influential faith-based platforms in the world. They explore how spiritual practice, digital innovation, and how a personal relationship with God are reshaping how we approach mental and emotional health. Whether you're religious, spiritual, or simply curious about how ancient rituals are finding new life through technology, this conversation will stretch your mind and open your heart.   **** Release details for the NEW BOOK.   Get your copy of Personal Socrates: Better Questions, Better Life   Connect with Marc >>>  Website | LinkedIn | Instagram |   Drop a review and let me know what resonates with you about the show! Thanks as always for listening and have the best day yet! * A special thanks to MONOS, our official travel partner for Behind the Human! Use MONOSBTH10 at check-out for savings on your next purchase. ✈️ * Special props

From Episode 195 with Archana SahIn this clip of the larger interview with Archana Sah, she covers the critical phases and elements of clinical trials—from phase one focusing on safety to phase three assessing effectiveness in diverse populations. Key aspects include the importance of the trial design, the role of comparator arms, regulatory requirements, patient recruitment, and the cultural preferences that influence trial protocols. The episode provides an in-depth look at how data is collected and analyzed to ensure the safety and efficacy of new drugs.00:00 Introduction to Clinical Trials00:26 Phases of Clinical Trials02:09 Designing Oncology Trials04:00 Protocol Design and Regulatory Approval05:27 Patient-Centric Considerations06:25 Vendor Roles and Statistical Analysis

In this explosive and highly anticipated episode, Dr. Roger McFillin hosts Dr. Ragy Girgis, a Columbia University Professor of Psychiatry and researcher, for a no-holds-barred confrontation that exposes the shocking divisions tearing apart the mental health field. What begins as a conversation about mass violence research rapidly explodes into a devastating examination of psychiatric medicine's crumbling foundations, questionable effectiveness, and devastating potential harms. The two clash in fierce, unrelenting disagreements over fundamental issues including the validity of DSM diagnoses, the debunked "chemical imbalance" theory of depression, dangerous SSRI safety cover-ups and black box warnings, corrupted research quality and pharmaceutical industry manipulation, and the catastrophic crisis of psychiatric drug overprescription poisoning 1 in 4-5 Americans. Dr. Girgis desperately defends traditional academic psychiatry and current treatment approaches, while Dr. McFillin ruthlessly dismantles the entire paradigm, arguing that the current system is systematically creating chronic mental illness rather than healing it. Buckle up for this brutal intellectual warfare.___________________________________________________________________________________________________________________________________________________Throughout the interview, Dr. Girgis repeatedly stated that "the data is clear" while dismissing contradictory evidence that challenges his conclusions. For our listeners' benefit, I have compiled research and documentation that directly disputes several of Dr. Girgis's key claims.Serotonin Hypothesis of Depression1. The serotonin theory of depression: a systematic umbrella review of the evidence (Moncrieff et al.)Conclusions: "This review suggests that the huge research effort based on the serotonin hypothesis has NOT produced convincing evidence of a biochemical basis to depression. This is consistent with research on many other biological markers . We suggest it is time to acknowledge that the serotonin theory of depression is NOT empirically substantiated."2.What has serotonin to do with depression?Conclusions: "Simple biochemical theories that link low levels of serotonin with depressed mood are no longer tenable."3. Is the chemical imbalance an ‘urban legend'? An exploration of the status of the serotonin theory of depression in the scientific literatureViolence & Suicide Associated with SSRI's 1. Precursors to suicidality and violence on antidepressants: systematic review of trials in adult healthy volunteers2. Prescription Drugs Associated with Reports of Violence Towards Others3. Antidepressant-induced akathisia-related homicides associated with diminishing mutations in metabolizing genes of the CYP450 family4. Lexapro Approved for Pediatric Use Despite the 6-Fold Increase in Suicide Risk5. McFillin Substack Review on Lexapro approved despite Suicide Risk6. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports7. Antidepressants Increase Suicide Attempts in Youth; No Preventative Effect8. Effect of selective serotonin reuptake inhibitor treatment following diagnosis of depression on suicidal behaviour risk:9.  FDA Warning: Antidepressants increase the risk of suicidal thinking and behavior (suicidality) in children and adolescents10.  Suicide Mortality in the United States, 2001–2021 CDC documentation11. US suicide rate reaches highest point in more than 80 years: See what latest data shows12.  CNN article reporting Eli Lilly Internal Documents"An internal document purportedly from Eli Lilly and Co. made public Monday appears to show that the drug maker had data more than 15 years ago showing that patients on its antidepressant Prozac were far more likely to attempt suicide and show hostility than were patients on other antidepressants and that the company attempted to minimize public awareness of the side effects. The 1988 document indicated that 3.7 percent of patients attempted suicide while on the blockbuster drug, a rate more than 12 times that cited for any of four other commonly used antidepressants.In addition, the paper said that 1.6 percent of patients reported incidents of hostility -- more than double the rate reported by patients on any of four other commonly used antidepressants."Examples of Violence after Prescription in legal system (Sample)January 24, 2020 – Newcastle, South Dublin, Ireland: Deirdre Morley, 44, smothered and killed her two sons Conor, 9, and Darragh, 7, and her three-year-old daughter Carla McGinley in their family home. She had been taking antidepressants since October 2018 and was admitted to St. Patrick's Mental Health Services on July 6, 2019, but was discharged after a short period, but was put on a combination of two antidepressants and a sedativeMay 11, 2018 – Osmington, Western Australia: Peter Miles, 61, shot his 35-year-old daughter and four grandchildren, aged 8 through 13, while they slept in their beds, in a shed that had been converted to a second house on the property. He then turned the gun on his 58-year-old wife in the living room of their house, before placing a call to police alerting them to his crimes. When they arrived, Miles was also found dead from a gunshot wound. Miles had started taking antidepressant medication just weeks before.April 6, 2018 – Wadsworth, Ohio: Gavon Ramsay, 17, strangled his neighbor, 98-year-old Margaret Douglas in her own home. His parents blame his actions on his having been misprescribed Zoloft. After a report by his school principal that the teen was depressed and might harm himself, he “returned to therapy,” and after a recommendation by a psychologist, the family's pediatrician prescribed the antidepressant Zoloft. From January through March leading up to the incident, the dosages were increased. During this time, his mother said she observed her son's behavior change—becoming increasingly irritable and hostile and saying bizarre things.October 21, 2013 – Sparks, Nevada: 12-year-old Jose Reyes opened fire at Sparks Middle School, killing a teacher and wounding two classmates be...

Today's guest is Michael Zaiac, Head of Medical Oncology for Europe and Canada at Daiichi Sankyo. Michael joins the platform in a special episode focused on how AI is driving measurable ROI in clinical trials—particularly in patient recruitment and eligibility. Their conversation explores how life sciences teams are applying advanced analytics to accelerate enrollment, improve diversity in study populations, and reduce time to trial completion. Michael also shares where generative AI is beginning to play a role in patient-facing materials, including simplified consent forms and study summaries. Throughout the episode, Michael emphasizes the importance of early stakeholder alignment, regulatory transparency, and the discipline required to deploy AI responsibly in high-risk clinical environments. This episode is sponsored by Medable. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast!

In this episode of the Diabetes Innovators Series, Rob interviews Jonathan Rigby, CEO of Sernova Biotherapeutics, about the innovative approaches to treating type 1 diabetes, particularly through the development of a biohybrid organ known as the cell pouch. Jonathan shares his personal journey as a type 1 diabetic and discusses the clinical trials, patient selection, and the future of diabetes treatment, including the challenges of immunosuppression and the complexities of daily diabetes management. The conversation emphasizes the importance of innovation in diabetes care and the hope for a future where patients can achieve insulin independence. Chapters 00:00 Introduction to Diabetes and Innovation 02:51 The Cell Pouch Biohybrid Organ 05:53 Clinical Trials and Patient Selection 08:48 Living with Type 1 Diabetes 11:51 Future of Diabetes Treatment 14:47 Immunosuppressants and Cell Acceptance 17:48 The Complexity of Diabetes Management 20:44 Conclusion and Future Outlook Resources: Sernova Jonathan Rigby LinkedIn

Gigi Robinson grew up with Ehlers-Danlos syndrome, a disease that turns your joints into overcooked spaghetti. Instead of letting it sideline her, she built a career out of telling the truth about invisible illness. We talk about what it takes to grow up faster than you should, why chronic illness is the worst unpaid internship, and how she turned her story into a business. You'll hear about her days schlepping to physical therapy before sunrise, documenting the sterile absurdity of waiting rooms, and finding purpose in the mess. Gigi's not interested in pity or polished narratives. She wants you to see what resilience really looks like, even when it's ugly. If you think you know what an influencer does, think again. This conversation will challenge your assumptions about work, health, and what it means to be seen.RELATED LINKSGigi Robinson Website: https://www.gigirobinson.comLinkedIn: https://www.linkedin.com/in/gigirobinsonInstagram: https://www.instagram.com/itsgigirobinsonTikTok: @itsgigirobinsonA Kids Book About Chronic Illness: https://akidsco.com/products/a-kids-book-about-chronic-illnessFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.